OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2023.13851 OL-25-6-13851 Review Metabolic biomarkers in lung cancer screening and early diagnosis (Review) XuYongjie 1 * DongXuesi 1 * QinChao 1 WangFei 1 CaoWei 1 LiJiang 1 YuYiwen 1 ZhaoLiang 1 TanFengwei 2 ChenWanqing 1 LiNi 1 HeJie 2 Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China Correspondence to: Dr Ni Li, Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Pan-jia-yuan South Lane, Chaoyang, Beijing 100021, P.R. China, E-mail: nli@cicams.ac.cn Dr Jie He, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Pan-jia-yuan South Lane, Chaoyang, Beijing 100021, P.R. China, E-mail: hejie@cicams.ac.cn

Contributed equally

 06 2023 03 05 2023 25 6 265 23082022 29032023 Copyright: © Xu et al. 2023 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Late diagnosis is one of the major contributing factors to the high mortality rate of lung cancer, which is now the leading cause of cancer-associated mortality worldwide. At present, low-dose CT (LDCT) screening in the high-risk population, in which lung cancer incidence is higher than that of the low-risk population is the predominant diagnostic strategy. Although this has efficiently reduced lung cancer mortality in large randomized trials, LDCT screening has high false-positive rates, resulting in excessive subsequent follow-up procedures and radiation exposure. Complementation of LDCT examination with biofluid-based biomarkers has been documented to increase efficacy, and this type of preliminary screening can potentially reduce potential radioactive damage to low-risk populations and the burden of hospital resources. Several molecular signatures based on components of the biofluid metabolome that can possibly discriminate patients with lung cancer from healthy individuals have been proposed over the past two decades. In the present review, advancements in currently available technologies in metabolomics were reviewed, with particular focus on their possible application in lung cancer screening and early detection.

 lung cancer metabolic biomarkers early diagnosis blood urine exhaled breath National Key Research and Development Program of China 2018YFC1315000 National Natural Science Foundation of China 82273722 The present study was funded by grants from the National Key Research and Development Program of China (grant no. 2018YFC1315000) and the National Natural Science Foundation of China (grant no. 82273722). Introduction

Lung cancer is one of the most common malignancies and is the leading cause of cancer-associated mortality worldwide (1). The poor prognosis and high mortality rate of lung cancer are mainly due to late diagnosis (2). At present, only ~15% of newly diagnosed lung cancer cases are diagnosed in the early stages (stages I–II), which contributes to >60% probability of 5-year survival when effective treatment is available (3–5). However, >60% patients with lung cancer are first diagnosed already in the advanced stages (stage IV) or already with metastatic tumors, who typically only have 5-year survival rates of <5% (6).

In addition to the reduction in exposure to tobacco smoke, screening for the early detection of lung cancer has been considered to be a major strategy for decreasing the rate of lung cancer mortality (7). At present, low-dose CT (LDCT) screening in the high-risk population is the predominant tool used for detecting lung cancer in the early stages (2). The results of the US National Lung Screening Trial (ClinicalTrials.gov number, NCT00047385) found that compared with chest X-ray examination, LDCT screening was associated with a 20% reduction in lung cancer-specific mortality in a high-risk group of participants defined by their smoking status (8). In addition, other previous studies have also confirmed the validity of LDCT screening for the early detection of lung cancer to reduce mortality rate (9,10). However, potentially healthy individuals are also at risk of being subjected to expensive and potentially harmful diagnostic procedures, such as positron emission tomography, transthoracic/bronchoscopic biopsy or even surgery, due to the considerably high false-positive rate of LDCT (nearly 96.4%) (8). Therefore, the combination of LDCT with additional biomarker-based tests has been proposed to be a more favorable strategy for improving the effectiveness of lung cancer screening programs whilst reducing the cost and harmfulness to otherwise healthy individuals (11). Such tests can either pre-select individuals from a high-risk population for LDCT examination or discriminate between benign and malignant pulmonary nodules detected by LDCT screening (12).

Several different components of blood, including specific serum/plasma proteins, autoantibodies, microRNA, cell-free DNA and circulating tumor cells, have all been proposed to be potential lung cancer biomarkers (13–15). However, they typically have low specificities and few were found for wider beneficial application in clinical practice, especially for the early detection of lung cancer. Instead, monitoring cancer-related metabolites is an emerging and promising approach for the detection and diagnosis of a number of malignant tumors, including colorectal, gastric, gynecological and lung cancer (16–20).

 Method

A search for articles published in English on PubMed (https://pubmed.ncbi.nlm.nih.gov/) was conducted regarding the use of metabolic biomarkers in lung cancer screening and early diagnosis that were published between Jan 1, 2002 and Aug 1, 2022. The search terms used were ‘lung cancer’, ‘metabolites’, and ‘early detection’. A total of 127 unique articles were identified and examined. Of these 127 articles, 25 were excluded due to being inappropriate article types, such as chapters in books, comments or review articles. Among the remaining 102 articles, 59 articles were removed due to being on unrelated topics, such as those not on lung cancer, not on cancer detection, not on metabolomics or not on biofluids (blood, urine and exhaled breath). Following evaluation of the full text of the remaining 43 articles, 12 were rejected, as these studies did not encompass early-stage lung cancer cases or it was unclear if early-stage lung cancer cases were included in the studies. Finally, the present review included 31 articles for analysis, as shown in the flow chart in Fig. 1.

 Metabolomics: A new source of cancer biomarkers

Metabolomics, also known as metabolic profiling, uses quantitative and qualitative analyses to determine key metabolism-associated molecules of different molecular masses (21,22). It reveals information into specific states of cancer that are otherwise not apparent (22). Previously, the assessment of metabolic changes is limited to measuring the levels of individual hormones and metabolites using imaging modalities and standard clinical laboratory tests (23). By contrast, metabolomics involves the measurement of vast numbers of metabolites systematically, including carbohydrates, nucleotides, carboxylic acids, amino acids and lipids in blood, urine, or other body fluids (24). Metabolomics has emerged to be a potentially powerful approach for identifying cancer biomarkers and drivers of tumorigenesis (25). In addition, compared with other ‘omes’, such as genome, transcriptome, and the proteome, the metabolome reflects the real-time status of a particular phenotype to reveal what exactly has happened in the organisms exactly, providing bona fide biomarkers for disease surveillance (Fig. 2).

 Metabolomics techniques and technologies

The main methodologies involved in metabolomics have been based on nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) techniques, coupled with either gas chromatography (GS) or liquid chromatography (LC), each with their specific advantages and limitations (Table I). NMR is highly selective and non-destructive, rendering it recognized to be the gold standard for elucidating the structure of metabolites. However, the sensitivity of NMR is relatively low, only being able to detect metabolites with concentrations >10−5 M (26). By contrast, MS has higher sensitivity and selectivity (26). Modern MS provides highly specific chemical information, such as accurate molecular mass, isotope distribution patterns for element formulation determination, and characteristic fragment-ion information directly related to the chemical structure of metabolites (27). In addition, the high sensitivity of MS allows for the detection and measurement of a large number of primary metabolites (the initial end products created by a live organism as a result of growth) and secondary metabolites (aid in the performance of various biological tasks that are not engaged in the growth and maintenance of cellular activity) at picomolar to femtomolar levels. As one of the major tools for the collection of ‘omic’ information, MS techniques use big data for processing and interpretation by machine learning (28,29). These unique advantages make MS an essential tool for metabolomics analysis (30). Over the past decade, various comprehensive reviews have already discussed how NMR and MS work, and how each can be used for metabolomics (31–33). Despite their own advantages and disadvantages, several studies have shown how they can be used to complement each other (31–35). Indeed, the use of multiple technologies greatly broadens the level of metabolite coverage and the types of samples that can be studied (36).

 Metabolomics for the early detection of lung cancer

Over the past two decades, a number of metabolomics studies have been performed based on NMR and/or MS techniques to generate metabolite profiles that can discriminate patients with lung cancer from healthy individuals using different types of biological samples. The present review summarizes the studies that include early-stage lung cancer cases to evaluate the viability of using metabolomics for the early detection of lung cancer.

<sec> <title>Blood metabolomics

Blood samples, including plasma and serum, are the most widely studied biological fluids for lung cancer research. It can be used for characterizing metabolic markers, using both targeted (measuring a specific set or family of compounds only) and untargeted (global profiling) approaches (Table II) (37–54).

Previous studies have described alterations in the levels of amino acids, especially in alanine, glutamine, histidine, leucine, isoleucine, lysine and serine, in the serum or plasma of patients with lung cancer (37–42,44). These alterations may be associated with the increase in amino acid demand caused by the proliferation of the tumor cells, highlighting the important role of amino acid metabolic pathways in lung cancer progression.

Lactic acid is another commonly altered metabolite in patients with lung cancer (37,39). Previous studies on lactate metabolism in patients with cancer have suggested that changes in the level of this metabolite are due to the increased glucose uptake and lactate production by the tumor in the absence of oxygen (55,56). In support of this, in various tumor cells such as lung carcinoma, renal carcinoma and gastric carcinoma cells, glucose is preferentially catabolized through fermentation into lactate even when oxygen is not limiting, in a phenomenon known as the Warburg effect (55,57).

Phospholipids are important constituents of the cell membrane (58). Phospholipid metabolic pathways are regularly found to be dysregulated in lung cancer, yielding distinct signatures (58). Several studies have revealed perturbed levels of phospholipids in the blood of patients with lung cancer (42,43,46,47,54). Yu et al (47) previously performed a study based on electrospray ionization-MS and found that lung cancer samples had significantly increased levels of lysophosphatidylethanolamine(18:1) and phosphatidylethanolamine(40:4), and decreased levels of cholesterol ester(18:2) and sphingomyelin(22:0) compared with those in healthy controls. The cancer classifier built using these four phospholipids was characterized by Area under the ROC Curve (AUC) values to be 82.3 and 80.8% in the training and validation set, respectively (47). Another previous study based on LC-MS encompassed 100 patients with early lung cancer and a matched group of 300 healthy individuals regarding sex, age and smoking exposure. Upregulation of phosphatidylcholines (PC), diacylophospholipids and SMs coupled with the downregulation of lysophosphatidylcholines (LPCs), such as LPC 18:2, LPC 18:1 and LPC 18:0 distinguished lung cancer cases from controls. An effective cancer classifier composed of seven components was built with an AUC of 0.88 (43). Recently, Wang et al (54) performed single-cell RNA sequencing of different early-stage lung cancers and found that global aberration of lipid metabolism in various cell types, including T cells, B cells, fibroblasts, endothelial cells and epithelial cells, with glycerophospholipid metabolism as the most altered (with the smallest P-value) lipid metabolism-related pathway. Untargeted lipidomics was performed in an exploratory cohort of 311 participants with nine phospholipids (LPC 16:0, 18:0 and 20:4; PC 16:0-18:1, 16:0-18:2, 18:0-18:1, 18:0-18:2 and 16:0-22:6; and triglycerides 16:0-18:1-18:1) being identified to be the features most beneficial for early lung cancer detection. Using these nine features, a LC-MS-based targeted assay achieved 100.0% specificity for early lung cancer detection on an independent validation cohort (54). In a hospital-based lung cancer screening cohort of 1,036 participants examined by LDCT and a prospective clinical cohort containing 109 participants, the assay reached ≥90.0% sensitivity and 92.0% specificity for the discrimination of patients with lung cancer compared with healthy controls (54).

 Urine metabolomics

Compared with other biospecimens, urine can be obtained from larger cohorts non-invasively and is therefore accepted more easily by the public. Similar to blood samples, urine also contains useful metabolic information for detecting the occurrence of lung cancer (59). The composition of urine is naturally less complex in comparison with that of plasma or serum, making it more popular for metabolomics analysis (59). In addition, once the blood is filtered by the glomerulus, certain components like metabolites can be concentrated in the urine, making their detection easier compared with that of other types of biological fluids. The first study to measure potential urinary metabolomic cancer biomarkers based on NMR and MS was published in 2006 and the concentration of nucleosides was found to be significantly increased in patients with breast cancer when compared with the normal controls (60). Carrola et al (61) first showed the valuable potential of using NMR-based metabolomics for finding putative biomarkers of lung cancer in the urine in 2011. Previous studies have since analyzed urinary metabolites employing either NMR or MS for early detection of lung cancer (Table II) (62–65).

The majority of urine metabolomic studies into patients with lung cancer found alterations in creatine and creatinine, making creatine and creatinine potentially valuable biomarkers for early lung cancer detection (61,63). To further assess whether creatine was elevated in the urine samples of subjects prior to lung cancer diagnosis, a detailed prospective study based on LC-MS was previously conducted (64). Urine samples from 178 patients with lung cancer and 351 volunteers were collected and examined, where it was revealed that elevated creatine levels were associated with lung cancer risk in both European- and African-Americans (64). Consistently, creatine and creatinine have been shown to be upregulated in other biofluids, such as serum and saliva, in patients with lung cancer (39,66). In the human body, creatine is synthesized from methionine, glycine, and arginine, which is then converted into creatinine (67). Therefore, the increase in creatine and creatinine levels may be associated with upregulated amino acid metabolism. Nevertheless, the promising results of urinary creatine and creatinine in early lung cancer detection remain to be validated by independent studies based on material collected real-time during lung cancer screening.

 Exhaled breath metabolomics

Normal metabolism produces a variety of volatile organic compounds (VOCs), which can be expelled through respiration (68). Therefore, exhaled breath has also been explored as a potential source of cancer biomarkers. It was first shown that VOCs in the exhaled breath could be used to differentiate patients with lung cancer from healthy individuals in 1999 (69). Since then, accumulating evidence has been supporting the utility of VOC detections in the exhaled breath for the early detection of lung cancer, most yielding high degrees of sensitivity and specificity (Table III) (70–78).

Lung cancer causes oxidative stress and induces oxidase enzymes in tumor tissues, which in turn produce higher concentrations of specific VOCs, especially carbonyl VOCs in the exhaled breath. Carbonyl VOCs are produced by biochemical pathways, such as the respiratory chain and oxidative phosphorylation pathway, as intermediates, some of which can yield unique information into specific pathways, such as lipid oxidation induced by free radicals (79,80).

Consequently, several studies have focused on the identification of carbonyl VOCs as markers of lung cancer in the exhaled breath (73,74,81). Fu et al (73) previously found that the concentrations of 2-butanone, 2-hydroxyacetaldehyde, 3-hydroxy-2-butanone and 4-hydroxyhexenal (4-HHE) in the exhaled breath of patients with lung cancer were significantly higher compared to those in the exhaled breath of healthy controls and patients with benign pulmonary nodules (BPN). This was found using Fourier transform-ion cyclotron resonance MS (73). Bousamra et al (81) then showed that the sensitivity and specificity of breath analysis was associated with the number of the elevated VOCs. Among patients with lung cancer, three or four elevated cancer markers (2-butanone, 2-hydroxyacetaldehyde, 3-hydroxy-2-butanone and 4-HHE) produced a specificity of 95% to discriminate patients with lung cancer from healthy controls. Furthermore, an enhanced model based on the elevated levels of the six carbonyl VOCs, including the four markers identified in Fu's work (73), plus acrolein and malondialdehyde, was found to effectively discriminate patients with lung cancer from healthy individuals in addition to patients with BPN (73). The sensitivity in each case was ≥96%, with specificity ranging from 64% for BPN to 86% for smokers and 100% for non-smokers and for the three groups combined 84% (74).

Other potential metabolic biomarkers that can be used for the early detection of lung cancer were also obtained in previous studies. Typical examples are isoprene, methanol and acetone (71,75,76). Despite these promising advances, the lack of normalization and standardization has led to significant variations in the VOC profiles and/or concentrations among the different studies and no commercial products have been used in clinical practice due to the lack of uniform sampling standards and sample storage methods.

 Conclusions

The metabolome is the most representative of the molecular phenotype of an organism, where the concentrations of metabolites directly reflect the current biochemical activity of the organism. Therefore, metabolomics is considered a suitable approach for increasing the efficacy of detecting early-stage lung cancer. However, such applications require a deeper understanding into how these measurements relate are associated with human physiology and cancer pathology. It remains to be elucidated which metabolites can be measured in biofluids which are readily accessible to accurately reflect cancer status. Although progress has been made, it remains unclear to what extent the metabolites in biofluids can reveal about the metabolic activity of the tumor. Additional metabolomics experiments in fluids associating these measurements to the physiology of cancer would be a promising future direction.

In addition, global metabolic alterations in biofluids do not allow for the differentiation of cancer from other diseases with systemic metabolic alterations such as hypercholesteremia and phenylketonuria. The issue of such confounding effects in metabolomic analysis will be minimized if the tumor tissues are tested appropriately using NMR and MS. Therefore, it would be of benefit to identify differentiating metabolites in tissues through untargeted metabolomics before testing them in the biofluids through targeted metabolomics. Several studies have recently highlighted the role of extracellular vesicles (EVs) and their cargo (protein and RNAs) in lung cancer diagnosis (82–85), proposing EVs to be another potential source of cancer biomarkers. Therefore, combined metabolomics approaches for EVs phenotyping would provide vital insights into the characteristics of EVs in cancer and potentially identify novel strategies for the early detection of lung cancer.

One of the challenges with metabolomics is the vast number and chemical complexity of metabolites that exist, such that no current metabolomics approach can cover these complexities comprehensively. This leads to inaccuracy in the early detection of lung cancer. The present review proposes that currently, the optimal metabolomics method for research would be combination with other ‘omics’ approaches to comprehensively elucidate the changes in metabolites in lung cancer whilst also to improve the accuracy of lung cancer screening.

 Acknowledgements

Not applicable.

 Availability of data and materials

Not applicable.

 Authors' contributions

YJX and XSD were involved in conceptualization, writing, and reviewing. CQ, FW and JL were involved in writing, and reviewing. YWY, LZ, FWT, WQC and WC were involved in reviewing and editing. JH and NL were involved in study concept and design, draft manuscript preparation and analysis and interpretation. All authors reviewed the paper and approved the final version of the manuscript. Data authentication is not applicable.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References SungHFerlayJSiegelRLLaversanneMSoerjomataramIJemalABrayFGlobal cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin71209249202110.3322/caac.2166033538338 International Early Lung Cancer Action Program InvestigatorsHenschkeCIYankelevitzDFLibbyDMPasmantierMWSmithJPMiettinenOSSurvival of patients with stage I lung cancer detected on CT screeningN Engl J Med35517631771200610.1056/NEJMoa06047617065637 Blandin KnightSCrosbiePABalataHChudziakJHussellTDiveCProgress and prospects of early detection in lung cancerOpen Biol7170070201710.1098/rsob.17007028878044 EggertJAPalavanzadehMBlantonAScreening and early detection of lung cancerSemin Oncol Nurs33129140201710.1016/j.soncn.2017.03.00128390841 ShlomiDAbudMLiranOBarJGai-MorNIlouzeMOnnABen-NunAHaickHPeledNDetection of lung cancer and EGFR mutation by electronic nose systemJ Thorac Oncol1215441551201710.1016/j.jtho.2017.06.07328709937 ArbourKCRielyGJSystemic therapy for locally advanced and metastatic non-small cell lung cancer: A ReviewJAMA322764774201910.1001/jama.2019.1105831454018 HoffmanPCMauerAMVokesEELung cancerLancet355479485200010.1016/S0140-6736(00)82038-310841143 National Lung Screening Trial Research TeamAberleDRAdamsAMBergCDBlackWCClappJDFagerstromRMGareenIFGatsonisCMarcusPMSicksJDReduced lung-cancer mortality with low-dose computed tomographic screeningN Engl J Med365395409201110.1056/NEJMoa110287321714641 PastorinoUSilvaMSestiniSSabiaFBoeriMCantaruttiASverzellatiNSozziGCorraoGMarchianoAProlonged lung cancer screening reduced 10-year mortality in the MILD trial: New confirmation of lung cancer screening efficacyAnn Oncol301672201910.1093/annonc/mdz11731168572 de KoningHJvan der AalstCMde JongPAScholtenETNackaertsKHeuvelmansMALammersJJWeeninkCYousaf-KhanUHorewegNReduced lung-cancer mortality with volume CT Screening in a randomized trialN Engl J Med382503513202010.1056/NEJMoa191179331995683 ChuGCWLazareKSullivanFSerum and blood based biomarkers for lung cancer screening: A systematic reviewBMC Cancer18181201810.1186/s12885-018-4024-329439651 PriolaAMPriolaSMGiaj-LevraMBassoEVeltriAFavaCCardinaleLClinical implications and added costs of incidental findings in an early detection study of lung cancer by using low-dose spiral computed tomographyClin Lung Cancer14139148201310.1016/j.cllc.2012.05.00522868220 HassaneinMRahmanJSChaurandPMassionPPAdvances in proteomic strategies toward the early detection of lung cancerProc Am Thorac Soc8183188201110.1513/pats.201012-069MS21543799 HassaneinMCallisonJCCallaway-LaneCAldrichMCGroganELMassionPPThe state of molecular biomarkers for the early detection of lung cancerCancer Prev Res (Phila)59921006201210.1158/1940-6207.CAPR-11-044122689914 SozziGBoeriMPotential biomarkers for lung cancer screeningTransl Lung Cancer Res3139148201425806293 SpratlinJLSerkovaNJEckhardtSGClinical applications of metabolomics in oncology: A reviewClin Cancer Res15431440200910.1158/1078-0432.CCR-08-105919147747 LiXKulkarniASLiuXGaoWQHuangLHuZQianKMetal-Organic framework hybrids aid metabolic profiling for colorectal cancerSmall Methods5e2001001202110.1002/smtd.20200100134927854 SuHLiXHuangLCaoJZhangMVedarethinamVDiWHuZQianKPlasmonic alloys reveal a distinct metabolic phenotype of early gastric cancerAdv Mater33e2007978202110.1002/adma.20200797833742513 PeiCLiuCWangYChengDLiRShuWZhangCHuWJinAYangYWanJFeOOH@Metal-Organic framework core-satellite nanocomposites for the serum metabolic fingerprinting of gynecological cancersAngew Chem Int Ed Engl591083110835202010.1002/anie.20200113532237260 DuarteIFRochaCMGilAMMetabolic profiling of biofluids: Potential in lung cancer screening and diagnosisExpert Rev Mol Diagn13737748201310.1586/14737159.2013.83557024063400 GermanJBHammockBDWatkinsSMMetabolomics: Building on a century of biochemistry to guide human healthMetabolomics139200510.1007/s11306-005-1102-816680201 ClishCBMetabolomics: An emerging but powerful tool for precision medicineCold Spring Harb Mol Case Stud1a000588201510.1101/mcs.a00058827148576 SchmidtDRPatelRKirschDGLewisCAVander HeidenMGLocasaleJWMetabolomics in cancer research and emerging applications in clinical oncologyCA Cancer J Clin71333358202110.3322/caac.2167033982817 LiuXLocasaleJWMetabolomics: A primerTrends Biochem Sci42274284201710.1016/j.tibs.2017.01.00428196646 RinschenMMIvanisevicJGieraMSiuzdakGIdentification of bioactive metabolites using activity metabolomicsNat Rev Mol Cell Biol20353367201910.1038/s41580-019-0108-430814649 TsedilinAMFakhrutdinovANEreminDBZalesskiySSChizhovAOKolotyrkinaNGAnanikovVPHow sensitive and accurate are routine NMR and MS measurements?Mendeleev Commun25454456201510.1016/j.mencom.2015.11.019 Dervilly-PinelGCourantFChereauSRoyerALBoyard-KiekenFAntignacJPMonteauFLe BizecBMetabolomics in food analysis: Application to the control of forbidden substancesDrug Test Anal4(Suppl 1)S59S69201210.1002/dta.134923949888 LiXJHaywardCFongPYDominguezMHunsuckerSWLeeLWMcLeanMLawSButlerHSchirmMA blood-based proteomic classifier for the molecular characterization of pulmonary nodulesSci Transl Med5207ra142201310.1126/scitranslmed.300701324132637 ZhangJRectorJLinJQYoungJHSansMKattaNGieseNYuWNagiCSuliburkJNondestructive tissue analysis for ex vivo and in vivo cancer diagnosis using a handheld mass spectrometry systemSci Transl Med9eaan3968201710.1126/scitranslmed.aan396828878011 LeiZHuhmanDVSumnerLWMass spectrometry strategies in metabolomicsJ Biol Chem2862543525442201110.1074/jbc.R111.23869121632543 WishartDSAdvances in metabolite identificationBioanalysis317691782201110.4155/bio.11.15521827274 ZhangASunHWangPHanYWangXModern analytical techniques in metabolomics analysisAnalyst137293300201210.1039/C1AN15605E22102985 DunnWBBaileyNJJohnsonHEMeasuring the metabolome: Current analytical technologiesAnalyst130606625200510.1039/b418288j15852128 PsychogiosNHauDDPengJGuoACMandalRBouatraSSinelnikovIKrishnamurthyREisnerRGautamBThe human serum metabolomePLoS One6e16957201110.1371/journal.pone.001695721359215 BouatraSAziatFMandalRGuoACWilsonMRKnoxCBjorndahlTCKrishnamurthyRSaleemFLiuPThe human urine metabolomePLoS One8e73076201310.1371/journal.pone.007307624023812 WishartDSEmerging applications of metabolomics in drug discovery and precision medicineNat Rev Drug Discov15473484201610.1038/nrd.2016.3226965202 RochaCMCarrolaJBarrosASGilAMGoodfellowBJCarreiraIMBernardoJGomesASousaVCarvalhoLDuarteIFMetabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasmaJ Proteome Res1043144324201110.1021/pr200550p21744875 DejaSPorebskaIKowalAZabekABargWPawelczykKStanimirovaIDaszykowskiMKorzeniewskaAJankowskaRMlynarzPMetabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary diseaseJ Pharm Biomed Anal100369380201410.1016/j.jpba.2014.08.02025213261 Puchades-CarrascoLJantus-LewintreEPerez-RamblaCGarcia-GarciaFLucasRCalabuigSBlascoADopazoJCampsCPineda-LucenaASerum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancerOncotarget71290412916201610.18632/oncotarget.735426883203 Ros-MazurczykMWojakowskaAMarczakLPolanskiKPietrowskaMPolanskaJDziadziuszkoRJassemJRzymanWWidlakPPanel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening-a pilot studyActa Biochim Pol64513518201710.18388/abp.2017_151728803255 KlupczynskaADerezinskiPGarrettTJRubioVYDyszkiewiczWKasprzykMKokotZJStudy of early stage non-small-cell lung cancer using Orbitrap-based global serum metabolomicsJ Cancer Res Clin Oncol143649659201710.1007/s00432-017-2347-028168355 ChenYMaZMinLLiHWangBZhongJDaiLBiomarker identification and pathway analysis by serum metabolomics of lung cancerBiomed Res Int2015183624201525961003 Ros-MazurczykMJelonekKMarczykMBinczykFPietrowskaMPolanskaJDziadziuszkoRJassemJRzymanWWidlakPSerum lipid profile discriminates patients with early lung cancer from healthy controlsLung Cancer1126974201710.1016/j.lungcan.2017.07.03629191603 KlupczynskaADerezinskiPDyszkiewiczWPawlakKKasprzykMKokotZJEvaluation of serum amino acid profiles' utility in non-small cell lung cancer detection in Polish populationLung Cancer1007176201610.1016/j.lungcan.2016.04.00827597283 LouisEAdriaensensPGuedensWBigirumurameTBaetenKVanhoveKVandeurzenKDarquennesKVansteenkisteJDoomsCDetection of lung cancer through metabolic changes measured in blood plasmaJ Thorac Oncol11516523201610.1016/j.jtho.2016.01.01126949046 MazzonePJWangXFBeukemannMZhangQSeeleyMMohneyRHoltTPappanKLMetabolite profiles of the serum of patients with non-small cell carcinomaJ Thorac Oncol117278201610.1016/j.jtho.2015.09.00226762741 YuZChenHAiJZhuYLiYBorgiaJAYangJSZhangJJiangBGuWDengYGlobal lipidomics identified plasma lipids as novel biomarkers for early detection of lung cancerOncotarget8107899107906201710.18632/oncotarget.2239129296211 XiangCJinSZhangJChenMXiaYShuYGuoRCortisol, cortisone, and 4-methoxyphenylacetic acid as potential plasma biomarkers for early detection of non-small cell lung cancerInt J Biol Markers33314320201810.1177/172460081877875429896992 KlupczynskaAPlewaSKasprzykMDyszkiewiczWKokotZJMatysiakJSerum lipidome screening in patients with stage I non-small cell lung cancerClin Exp Med19505513201910.1007/s10238-019-00566-731264112 ZhangLZhengJAhmedRHuangGReidJMandalRMaksymuikASitarDSTappiaPSRamjiawanBA High-Performing plasma metabolite panel for early-stage lung cancer detectionCancers (Basel)12622202010.3390/cancers1203062232156060 HuangLWangLHuXChenSTaoYSuHYangJXuWVedarethinamVWuSMachine learning of serum metabolic patterns encodes early-stage lung adenocarcinomaNat Commun113556202010.1038/s41467-020-17347-632678093 DerveauxEThomeerMMesottenLReekmansGAdriaensensPDetection of lung cancer via blood plasma and 1H-NMR metabolomics: Validation by a semi-targeted and quantitative approach using a protein-binding competitorMetabolites11537202110.3390/metabo1108053734436478 QiSAWuQChenZZhangWZhouYMaoKLiJLiYChenJHuangYHuangYHigh-resolution metabolomic biomarkers for lung cancer diagnosis and prognosisSci Rep1111805202110.1038/s41598-021-91276-234083687 WangGQiuMXingXZhouJYaoHLiMYinRHouYLiYPanSLung cancer scRNA-seq and lipidomics reveal aberrant lipid metabolism for early-stage diagnosisSci Transl Med14eabk2756202210.1126/scitranslmed.abk275635108060 WarburgOOn the origin of cancer cellsScience123309314195610.1126/science.123.3191.30913298683 MathupalaSPKoYHPedersenPLHexokinase-2 bound to mitochondria: Cancer's stygian link to the ‘Warburg Effect’ and a pivotal target for effective therapySemin Cancer Biol191724200910.1016/j.semcancer.2008.11.00619101634 DangCVLinks between metabolism and cancerGenes Dev26877890201210.1101/gad.189365.11222549953 RochaCMBarrosASGilAMGoodfellowBJHumpferESpraulMCarreiraIMMeloJBBernardoJGomesAMetabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopyJ Proteome Res9319332201010.1021/pr900657419908917 MaksymiukAWTappiaPSSitarDSAkhtarPSKhatunNParveenRAhmedRAhmedRBChengBHuangGUse of amantadine as substrate for SSAT-1 activity as a reliable clinical diagnostic assay for breast and lung cancerFuture Sci OA5FSO365201810.4155/fsoa-2018-010630820345 ChoSHJungBHLeeSHLeeWYKongGChungBCDirect determination of nucleosides in the urine of patients with breast cancer using column-switching liquid chromatography-tandem mass spectrometryBiomed Chromatogr2012291236200610.1002/bmc.68916799933 CarrolaJRochaCMBarrosASGilAMGoodfellowBJCarreiraIMBernardoJGomesASousaVCarvalhoLDuarteIFMetabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urineJ Proteome Res10221230201110.1021/pr100899x21058631 HanaiYShimonoKMatsumuraKVachaniAAlbeldaSYamazakiKBeauchampGKOkaHUrinary volatile compounds as biomarkers for lung cancerBiosci Biotechnol Biochem76679684201210.1271/bbb.11076022484930 MatheEAPattersonADHaznadarMMannaSKKrauszKWBowmanEDShieldsPGIdleJRSmithPBAnamiKNoninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancerCancer Res7432593270201410.1158/0008-5472.CAN-14-010924736543 HaznadarMCaiQKrauszKWBowmanEDMargonoENoroRThompsonMDMatheEAMunroHMSteinwandelMDUrinary metabolite risk biomarkers of lung cancer: A prospective cohort studyCancer Epidemiol Biomarkers Prev25978986201610.1158/1055-9965.EPI-15-119127013655 FunaiKHonzawaKSuzukiMMomikiSAsaiKKasamatsuNKawaseAShinkeTOkadaHNishizawaSTakamotoHUrinary fluorescent metabolite O-aminohippuric acid is a useful biomarker for lung cancer detectionMetabolomics16101202010.1007/s11306-020-01721-y32940815 JiangXChenXChenZYuJLouHWuJHigh-Throughput salivary metabolite profiling on an ultralow noise tip-enhanced laser desorption ionization mass spectrometry platform for noninvasive diagnosis of early lung cancerJ Proteome Res2043464356202110.1021/acs.jproteome.1c0031034342461 SlackAYeomanAWendonJRenal dysfunction in chronic liver diseaseCrit Care14214201010.1186/cc885520236458 FarraiaMVCavaleiro RufoJPacienciaIMendesFDelgadoLMoreiraAThe electronic nose technology in clinical diagnosis: A systematic reviewPorto Biomed J4e42201910.1097/j.pbj.000000000000004231930178 PhillipsMGleesonKHughesJMGreenbergJCataneoRNBakerLMcVayWPVolatile organic compounds in breath as markers of lung cancer: A cross-sectional studyLancet35319301933199910.1016/S0140-6736(98)07552-710371572 PhillipsMCataneoRNCumminARGagliardiAJGleesonKGreenbergJMaxfieldRARomWNDetection of lung cancer with volatile markers in the breathChest12321152123200310.1378/chest.123.6.211512796197 PoliDCarbognaniPCorradiMGoldoniMAcampaOBalbiBBianchiLRuscaMMuttiAExhaled volatile organic compounds in patients with non-small cell lung cancer: Cross sectional and nested short-term follow-up studyRespir Res671200510.1186/1465-9921-6-7116018807 PhillipsMAltorkiNAustinJHCameronRBCataneoRNGreenbergJKlossRMaxfieldRAMunawarMIPassHIPrediction of lung cancer using volatile biomarkers in breathCancer Biomark395109200710.3233/CBM-2007-320417522431 FuXALiMKnippRJNantzMHBousamraMNoninvasive detection of lung cancer using exhaled breathCancer Med3174181201410.1002/cam4.16224402867 LiMYangDBrockGKnippRJBousamraMNantzMHFuXABreath carbonyl compounds as biomarkers of lung cancerLung Cancer909297201510.1016/j.lungcan.2015.07.00526233567 SakumuraYKoyamaYTokutakeHHidaTSatoKItohTAkamatsuTShinWDiagnosis by volatile organic compounds in exhaled breath from lung cancer patients using support vector machine algorithmSensors (Basel)17287201710.3390/s1702028728165388 RudnickaJKowalkowskiTBuszewskiBSearching for selected VOCs in human breath samples as potential markers of lung cancerLung Cancer135123129201910.1016/j.lungcan.2019.02.01231446984 ChenXMuhammadKGMadeehaCFuWXuLHuYLiuJYingKChenLYurievnaGOCalculated indices of volatile organic compounds (VOCs) in exhalation for lung cancer screening and early detectionLung Cancer154197205202110.1016/j.lungcan.2021.02.00633653598 TsouPHLinZLPanYCYangHCChangCJLiangSKWenYFChangCHChangLYYuKLExploring volatile organic compounds in breath for high-accuracy prediction of lung cancerCancers (Basel)131431202110.3390/cancers1306143133801001 HakimMBrozaYYBarashOPeledNPhillipsMAmannAHaickHVolatile organic compounds of lung cancer and possible biochemical pathwaysChem Rev11259495966201210.1021/cr300174a22991938 FanTWLaneANHigashiRMFaragMAGaoHBousamraMMillerDMAltered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM)Mol Cancer841200910.1186/1476-4598-8-4119558692 BousamraMIISchumerELiMKnippRJNantzMHvan BerkelVFuXAQuantitative analysis of exhaled carbonyl compounds distinguishes benign from malignant pulmonary diseaseJ Thorac Cardiovasc Surg14810741080discussion 1080-1201410.1016/j.jtcvs.2014.06.00625129599 ParamananthamAAsfiyaRDasSMcCullyGSrivastavaAExtracellular Vesicle (EVs) associated non-coding RNAs in lung cancer and therapeuticsInt J Mol Sci2313637202210.3390/ijms23211363736362424 HuaYDaiCHeQCaiXLiMAutoantibody panel on small extracellular vesicles for the early detection of lung cancerClin Immunol245109175202210.1016/j.clim.2022.10917536356847 CammarataGde Miguel-PerezDRussoAPelegADoloVRolfoCTavernaSEmerging noncoding RNAs contained in extracellular vesicles: Rising stars as biomarkers in lung cancer liquid biopsyTher Adv Med Oncol1417588359221131229202210.1177/1758835922113122936353504 Pedraz-ValduncielCGiannoukakosSGimenez-CapitanAFortunatoDFilipskaMBertran-AlamilloJBrachtJWPDrozdowskyjAValarezoJZarovniNMultiplex Analysis of CircRNAs from plasma extracellular vesicle-enriched samples for the detection of early-stage non-small cell lung cancerPharmaceutics142034202210.3390/pharmaceutics1410203436297470

Flow chart depicting the identification and selection of articles.

Relationship between -omes with systems biology. Cancer is caused by changes at the genomic level which results in altered RNA transcription, protein expression and function. The metabolome reflects the real-time status of phenotype and reveals what exactly has happened in the organisms.

Comparison between NMR and MS.

Properties NMR MS
Sensitivity Low High, at picomolar and femtomolar levels
Selectivity Generally used for non-selective analysis Generally used for selective and non-selective (targeted and untargeted) analysis
Sample measurement All metabolites with NMR concentration levels can be detected in one assay Different chromatographic techniques are required for different types of metabolites
Sample recovery i) Non-destructive; and i) Destructive; and ii) samples can't be
ii) samples can be recovered and stored for a long recovered
period; iii) samples can be analyzed multiple times
Reproducibility High Moderate
Sample preparation Small sample volumes i) High quality of sample preparation; and
ii) different columns and optimized ionization conditions are required
Number of metabolites detected 40-200, depending on spectral resolution ≥500

NMR, nuclear magnetic resonance; MS, mass spectrometry.

List of metabolic studies of blood and urine applied to lung cancer.

A, Serum and plasma
First author, year Research subjects Analytical techniques Major findings (Refs.)
Rocha et al, 2011 85 LC (69 eLC) and 78 CTR NMR Compared with CTR samples, LC samples had significantly: i) Higher levels of LDL, VLDL, lactic acid and pyruvic acid; and ii) lower levels of HDL, glucose, citrate, formate, acetate, amino acids (such as alanine, glutamine and histidine) and methanol (37)
Deja et al, 2014 77 LC (35 eLC) and 22 COPD NMR Compared with COPD samples, LC samples had significantly: i) Higher levels of N-acetylated glycoproteins, leucine, lysine, mannose, choline and lipids; and ii) lower levels of acetate, citrate and methanol (38)
Klupczynska et al, 2016 90 LC (70 eLC) and 63 CTR Liquid chromatography-MS A new set of six amino acids (aspartic acid, β-alanine, histidine, asparagine, phenylalanine and serine) ensured higher accuracy to distinguish LC from CTR (from 90.3 to 77.1% depending on the histological type) (44)
Puchades-Carrasco et al, 2016 142 LC (72 eLC) and 87 CTR NMR Compared with CTR samples, LC samples had significantly: i) Higher levels of leucine/isoleucine, acetate, N-acetyl-cysteine, glutamate, methanol, glycerol, creatine and lactic acid; and ii) lower levels of HDL, LDL, VLDL, adipic acid, lipids, glutamine, Choline–N(CH3)3, threonine and histidine (39)
Louis et al, 2016 331 LC (93 eLC) and 315 CTR NMR Compared with CTR samples, LC samples had significantly: i) Higher levels of glucose, N-acetylated glycoproteins, b-hydroxybutyrate, leucine, lysine, tyrosine, threonine, glutamine, valine and aspartate; and ii) lower levels of alanine, lactate, sphingomyelin and phosphatidylcholine (and other cholinated phospholipids), citrate and other phospholipids (45)
Klupczynska et al, 2017 50 eLC and 25 CTR UHPLC-Q-Orbitrap-HRMS In total, 36 metabolites were significantly altered between LC and CTR samples, including carnitine, acyl-carnitines, malic acid, pyroglutamic acid, histidine and histamine. A signature consisting of 12 of these identified metabolites allowed the building of a cancer classifier characterized by a receiver operating characteristic AUC value of 0.836 (41)
Ros-Mazurczyk et al, 2017 31 LC (25 eLC) and 92 CTR GC-MS Compared with CTR samples, LC samples had significantly: i) Higher levels of benzaldehyde; and ii) lower levels of 17 metabolites, including amino acids, carboxylic acids and alcohols (40)
Chen et al, 2015 30 LC (22 eLC) and 30 CTR GC-MS and liquid chromatography-MS Compared with CTR samples, LC samples had significantly: i) Higher levels of phosphorylcholine, glycerophospho-N-arachidonoyl, ethanolamine, γ-linolenic acid, α-hydroxyisobutyric acid and 9,12-octadecadienoic acid; and ii) lower levels of prasterone sulphate, sphingosine, serine and 2,3,4-trihydroxybutyric acids (42)
Mazzone et al, 2016 94 LC (57 eLC) and 190 CTR GC-MS and liquid chromatography-MS 79 metabolites significantly increased and 70 metabolites decreased in the LC group. In total, the ratios of 9,723 metabolites differed significantly between the LC and CTR groups (46)
Yu et al, 2017 199 eLC and 147 CTR ESI-MS LC samples had significantly increased levels of LPE(18:1) and ePE(40:4) but decreased levels of C(18:2)CE and SM(22:0) compared with those in CTR samples (47)
Ros-Mazurczyk et al, 2017 100 eLC and 300 CTR MALDI-MS and liquid chromatography-MS PC, diacylophospholipids and SMs were frequently upregulated, whilst LPC 18:2, LPC 18:1 and LPC 18:0 were significantly downregulated in LC samples (43)
Xiang et al, 2018 99 LC (33 eLC) and 112 CTR Liquid chromatography-MS In total, 28 endogenous metabolites were present at significantly different levels in patients with LC compared with those in CTR group. Cortisol, cortisone and 4-methoxyphenylacetic acid had high sensitivity and specificity values (AUC=0.955) as biomarkers for discriminating between LC and CTR (48)
Klupczynska et al, 2019 20 eLC and 20 CTR Liquid chromatography-MS Compared with CTR samples, LC samples had significantly: i) Higher levels of PC (PC 42:4, 42:1, 44:3 and 40:2) and LPC (LPC 26:0 and 26:1); and ii) lower levels of PC 34:4. A biomarker panel of the seven aforementioned metabolites was able to distinguish eLC from CTR with a sensitivity of 70–90% and a specificity of 90–93% (49)
Zhang et al, 2020 156 LC (130 eLC) and 60 CTR Liquid chromatography-MS β-hydroxybutyric acid, LPC 20:3, PC acyl ester C40:6, citric acid and fumaric acid were significantly different between CTR and eLC samples (50)
Huang et al, 2020 200 eLC and 200 CTR LDI-MS Compared with CTR samples, LC samples had significantly: i) Higher levels of cystenie, histamine, fatty acid, uracil and uric acid; and ii) Lower levels of hydroxypicolinic acid and indoleacrylic acid. A biomarker panel of these seven metabolites was able to distinguish eLC from CTR with a sensitivity of 70–90% and a specificity of 90–93% (51)
Derveaux et al, 2021 114 LC (48 eLC) and 118 CTR NMR In total, 62 metabolites, including lactate, valine, alanine, maleic acid and phenylalanine, were significantly different between LC and CTR samples (52)
Qi et al, 2021 98 LC (52 eLC) and 75 CTR Liquid chromatography-MS In total, five metabolites (palmitic acid, heptadecanoic acid, 4-oxoproline, tridecanoic acid and ornithine) had the potential for early lung cancer screening. The discrimination accuracy and AUC score reached as high as 0.829 and 0.869 (53)
Wang et al, 2022 171 eLC and 140 CTR Liquid chromatography-MS In total, nine lipids (LPC 16:0, 18:0 and 20:4; PC 16:0-18:1, 16:0-18:2, 18:0-18:1, 18:0-18:2; and 16:0-22:6 and triglycerides 16:0-18:1) were identified as the features most important for early-stage cancer detection (54)
B, Urine
First author, year Research subjects Analytical techniques Major findings (Refs.)
Hanai et al, 2012 20 LC (11 eLC) and 20 CTR GC-MS Tetrahydrofuran, 2-chloroethanol, 2-pentanone, 2-methylpyrazine, cyclohexanone, 2-ethyl-1-hexanol, 2-phenyl-2-propanol, isophorone and 2,6-diisopropylphenol were significantly upregulated in LC samples (62)
Mathe et al, 2014 469 LC (211 eLC) and 536 CTR UPLC-ESI-QTOF-MS Levels of creatine riboside, nacetylneuraminic acid, cortisol sulfate and an unidentified glucuronidated compound referred to as ‘561+’ were significantly elevated in the LC group (63)
Haznadar et al, 2016 178 LC (28 eLC) and 351 CTR Liquid chromatography-MS Creatine riboside was associated with lung cancer risk in the overall case-control set, whilst creatine riboside and nacetylneuraminic acid were associated with lung cancer risk in a European-American cohort (64)
Funai et al, 2020 46 LC (23 eLC) and 185 CTR Liquid chromatography-MS and NMR O-aminohippuric acid was significantly upregulated in LC samples compared with that in CTR samples (65)

LC, lung cancer; eLC, early lung cancer; CTR, control; COPD, chronic obstructive pulmonary disease; NMR, nuclear magnetic resonance; MS, mass spectrometry; GC-MS, gas chromatography-MS; UHPLC-Q-Orbitrap-HRMS, ultra-high-performance liquid chromatography-quadrupole-Orbitrap-high-resolution MS; ESI, electrospray ionization; MALDI, Matrix-Assisted Laser Desorption Ionization; LDI, laser desorption/ionization; UPLC-ESI-QTOF, ultraperformance liquid chromatography-electrospray-ionization-quadrupole time-of-flight; AUC, area under the curve; LDL, low density lipoprotein; VLDL, very low-density lipoprotein; HDL, high-density lipoprotein; PC, phosphatidylcholines; LPC, lysophosphatidylcholine; SM, sphingomyelin.

Metabolic studies of exhaled breath applied to LC.

First author, year Research subjects Analytical techniques Major Findings Sensitivity, % Specificity, % (Refs.)
Phillips et al, 1999 87 LC (16 eLC) and 91 CTR GC-MS A predictive model employing nine VOCs (butane, tridecane, tridecane, octane, hexane, heptane, hexane, pentane and decane) exhibited sufficient sensitivity and specificity to be considered as a screen for LC in a high-risk population 85.1 80.5 (70)
Poli et al, 2005 36 eLC, 25 COPD and 50 CTR GC-MS The combination of the 13 VOCs allowed the correct classification of the cases into groups. Together with conventional diagnostic approaches, VOC analysis could be used as a complementary test for the early diagnosis of LC 72.2 93.6 (71)
Phillips et al, 2007 193 LC (120 eLC) and 211 CTR GC-MS Mean typicality scores employing a 16-VOC model were significantly higher in patients with LC compared with those in the control group. The predictive model achieved near-maximal performance with six breath VOC 84.6 80. (72)
Fu et al, 2014 97 LC (50 eLC), 32 BPN and 88 CTR FT-ICR-MS The concentrations of 2-butanone, 2-hydroxyacetaldehyde, 3-hydroxy-2-butanone and 4-hydroxyhexenal in the exhaled breath of patients with LC were significantly higher compared with that in the BPN and CTR samples 89.8 81.3 (73)
Li et al, 2015 85 LC (44 eLC), 34 BPN and 85 CTR FT-ICR-MS A model based on elevated levels of the six carbonyl VOCs (2-butanone, 2-hydroxyacetaldehyde, 3-hydroxy-2-butanone, 4-hydroxyhexenal, acrolein and malondialdehyde) effectively discriminates patients with LC from healthy controls in addition to patients with BPN 96 84 (74)
Sakumura et al, 2017 107 LC (70 eLC) and 29 CTR GC-MS In total, 68 VOCs were detected as LC markers and a combination of five VOCs (CHN, methanol, CH3CN, isoprene and 1-propanol) was sufficient for 89.0% screening accuracy 95 89 (75)
Rudnicka et al, 2019 108 LC (17 eLC) and 121 CTR GC-MS In total, 88 VOCs were identified in the exhaled breath. The statistical analysis revealed seven analytes (acetone, methyl acetate, isoprene, methyl vinyl ketone, cyclohexane, 2-methylheptane and cyclohexanone) to have the highest discriminatory power Validation group, 80; test group, 86.4 Validation group, 91.2; test group, 86.4 (76)
Chen et al, 2021 160 LC (74 eLC), 70 BPN and 122 CTR GC-MS In total, 20 VOCs discriminated LC from CTR (AUC=0.987); 19 VOCs discriminated LC from BPN (AUC=0.809) NR NR (77)
Tsou et al, 2021 148 LC (8 eLC) and 168 CTR SIFT-MS In total, 116 VOCs were analyzed in the exhaled breath samples and a quantitative VOCs databank integrated with the application of an XGBoost classifier (a machine learning method) provided a persuasive platform for lung cancer prediction 96 88 (78)

LC, lung cancer; eLC, early lung cancer; CTR, control; COPD, chronic obstructive pulmonary disease; BPN, benign pulmonary nodules; GC-MS, gas chromatography-mass spectrometry; NR, not reported; FT-ICR-MS, Fourier transform-ion cyclotron resonance mass spectroscopy; SIFT-MS, selected ion flow tube mass spectrometry; VOC, volatile organic compound; AUC, area under the curve.